JSM Activity #155

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

Back to main JSM 2002 Program page


Activity ID:  155
Title
* Issues in Drug Development
Date / Time / Room Sponsor Type
08/12/2002
2:00 PM - 3:50 PM
Room: H-Mercury Ballroom 		Biopharmaceutical Section*, ENAR Contributed
Organizer: n/a
Chair: Balasamy Thiyagarajam, Merck & Company, Inc.
Discussant:  
Description

Statistical issues involved in drug development including assessing dose response and evaluating drug safety.
  301692  By:  Yili   Lu 2:05 PM 08/12/2002
Duration Estimation for A Treatment-Emergent Adverse Event

  301735  By:  A. Lawrence Gould 2:20 PM 08/12/2002
Using Order Statistics in Clinical Trial Safety Evaluation

  301928  By:  Qian  Li 2:35 PM 08/12/2002
Problems in Combining Studies for Safety Analyses

  301931  By:  Tom  Hammerstrom 2:50 PM 08/12/2002
Power of Different Endpoints in HIV Trials

  300974  By:  Frank  Bretz 3:05 PM 08/12/2002
Identifying Effective and/or Safe Doses by Stepwise Confidence Intervals for Ratios

  300985  By:  Bill  Pikounis 3:20 PM 08/12/2002
Effective Dose Estimation with Multi-Factor Models

  300486  By:  Kao-Tai  Tsai 3:35 PM 08/12/2002
Q-TWiST Analysis for Neoadjuvant Cancer Trials

JSM 2002

For information, contact meetings@amstat.org or phone (703) 684-1221.

If you have questions about the Continuing Education program, please contact the Education Department.

Revised March 2002